For More Information: Michael P. Gray Jenny Viscarolasaga Chief Financial Officer For Curis, Inc. Curis, Inc. 617-503-6658 617-503-6632 Jenny@tworoadscommunications.com mgray@curis.com Curis Announc

Curis Announces Key Management Promotions

Michael Gray appointed COO and Dr. Changgeng Qian promoted to the position of Vice President,

Discovery and Preclinical Development

CAMBRIDGE, Mass. December 20, 2006 Curis,

Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, today announced recent promotions within its management team infrastructure. The changes were made to better align

the management structure with Curis ongoing strategy of deemphasizing early stage discovery research and seeking instead to develop proprietary later stage preclinical and, ultimately, clinical assets. The first such later stage program is a

platform of proprietary cancer programs that target multiple validated cancer pathways. This platform is currently in preclinical testing and Curis expects to select the first lead clinical candidate in early 2007 and file an Investigational New

Drug (IND) application during the second half of 2007.

Management Promotions

Michael P. Gray, who most recently held the position of Senior Vice President of Finance and Chief Financial Officer, will assume the additional role of Chief Operating Officer, while retaining the responsibilities

and title of Chief Financial Officer. Gray will continue to have primary responsibility over a majority of Curis administrative functions and will now have a greater role in aligning Curis promising drug development programs with the

company s overall corporate objectives and operating budget.

Mike Gray has been an important part of the Curis team and has consistently

demonstrated strong management and leadership skills during his tenure, said Dan Passeri, President and Chief Executive Officer of Curis. He has provided solid financial and administrative oversight throughout his three years as

Curis Chief Financial Officer and was also instrumental in implementing various aspects of our recent entry into China. I will be looking to Mike to lead the coordination of the company s drug development and administrative efforts as we

seek to move our drug programs into later stages of development in a highly effective and cost-efficient manner.

In addition, Curis recently

promoted Dr. Changgeng Qian to the position of Vice President, Discovery and Preclinical Development. Dr. Qian joined Curis in 2001, bringing more than 25 years of academic and industrial experience in drug discovery, including

pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety

assessment. He has played key roles in the discovery and development of several drug candidates, including cancer and central nervous system indications at CytoMed, Inc., LeukoSite, Inc., and Millennium Pharmaceuticals, Inc.

Noted Passeri, Dr. Qian brings tremendous experience and scientific leadership to his new role. He has been an invaluable asset to Curis, both in his guidance

surrounding Curis programs under collaboration, and in his leadership in directing Curis wholly-owned and proprietary multi-targeted inhibitor (MTI) programs. We are extremely pleased to have someone of Dr. Qian s caliber

leading these scientific efforts.

About Curis Multi-Targeted Inhibitor Cancer Programs

Earlier in 2006, Curis announced a strategic transition under which it has deemphasized early discovery research programs and instead focused its efforts on seeking to

develop drug candidates from later stages of preclinical testing into human clinical trials. In addition to Curis Hedgehog-based programs currently under development with Genentech, Wyeth, and Proctor & Gamble, Curis is seeking to

develop several classes of new proprietary small molecule drug candidates, each of which is designed to target multiple distinct molecular pathways.

believes that some of the most effective therapies currently marketed are those that attack cancer from multiple directions simultaneously. In addition, Curis believes that multi-targeting has an additional advantage because such therapies may help

reduce the emergence of drug resistant populations of cells within the tumor. Unlike other recent multi-targeted inhibitors, which target multiple, closely-related tyrosine kinase receptors, Curis drugs are being developed as single molecules

that target multiple distinct validated molecular pathways which Curis believes will provide anti-tumor activity across a broad range of hematologic (i.e. blood) and solid tumor cancers.

Curis anticipates that its multi-targeted pathway inhibitors may have the potential to improve efficacy, prevent the emergence of drug resistance, and/or decrease the

dose-limiting toxicities, possibly by virtue of the ability to reduce dosing frequency or amount. Further, Curis believes that these new inhibitors may represent a new paradigm in rational multi-pathway targeting drug development.

Curis expects that the cost efficiencies of its Chinese operations will allow continued development of these cancer programs as well as additional future drug programs.

These additional drug programs may be developed internally or acquired through in-licensing activities.

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory

pathways that control repair and regeneration. Curis product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce

several promising drug product candidates in the fields of cancer (under collaboration with

Genentech, as well new proprietary cancer programs that target multiple validated cancer pathways), neurological

disorders (under collaboration with Wyeth), hair growth (under collaboration with Procter & Gamble), kidney and other diseases (licensed to Ortho Biotech Products and under development at Centocor, both subsidiaries of Johnson &

Johnson), as well as cardiovascular disease. For more information, please visit www.curis.com.

Cautionary Statement: This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995, including statements concerning Curis expectation that it will select the first lead clinical candidate under its MTI program in early 2007, Curis expectation that it will file an

IND on the first lead clinical candidate under its MTI program during the second half of 2007, Curis belief that its MTI programs will provide anti-tumor activity in a broad range of hematologic and solid tumors, Curis anticipation that

its MTI programs may improve efficacy, prevent the emergence of drug resistance, and decrease dose-limiting toxicities, and Curis belief that its MTI programs may represent a new paradigm in rational multi-pathway targeting drug development.

Forward-looking statements used in this press release may contain the words believes , expects , anticipates , plans , seeks , estimates or similar expressions. These forward-looking

statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that may cause the Company s actual results to be materially different from those indicated by such forward-looking statements

including, among other things:

In addition, any forward-looking statements represent the Company s views only as of today and should not be

relied upon as representing its views as of any subsequent date. The Company disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future

events or otherwise.